2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, discusses approaching patients with HPV-positive head and neck cancer.
Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, discusses approaching patients with HPV-positive head and neck cancer.
HPV-positive patients tend to have a better prognosis, states Gold. Currently, HPV status is not used as a factor to select treatment options. As research continues, patients may receive less treatment to spare long-term toxicities.
According to Gold, patients who come in with locally advanced disease, can be treated with chemoradiation—which are the vast majority of patients. Chemoradiation of HPV-negative cancer does not have great overall survival; it is only about 40% at 5 years. For HPV-positive cancer—especially nonsmokers—85% of those patients are cured.